Allorion Therapeutics, a biotech startup based in Natick, Massachusetts, has secured $50 million in Series B funding from investors including Qiming Venture Partners USA, Octagon Capital Srl, 3SBio Inc., Long River Investment Management Limited, and INCE Capital. The funding will advance the company's research and development efforts in small molecule drugs for cancer and autoimmune diseases.

Led by a team of cancer biology and drug development experts, Allorion Therapeutics focuses on discovering modulators for well-validated targets with clear clinical development routes. The company also prioritizes building innovative data and screening platforms for sustainable success and constructing chemical libraries with the aid of AI.

With dual sites in Natick, Massachusetts, and Guangzhou, China, Allorion Therapeutics is well-positioned to expand its global reach in the biotech industry.

The company's dedication to advancing the field of cancer and autoimmune disease research makes it an exciting player to watch in the coming years. Check this link for the Latest Funding round of Allorion Therapeutics: https://founderlodge.com/round/Allorion-Therapeutics-raises-50000000-Series-B-2023-03-13-Fang-Li-MTA3MjM.